Leukocyte as an adequate model for studying changes in energy metabolism in heart cells under the influence of cardiocytoprotectors in myocardial ischemia
A. L. Khokhlov,
O. V. Romashchenko,
V. V. Rumbesht,
T. I. Yakunchenko,
N. I. Zhernakova,
L. R. Zakirova,
V. G. Kukes https://doi.org/10.29413/ABS.2024-9.5.12
Abstract
The aim of this study was to determine the possibility of studying the nature of the influence of cardiocytoprotectors on energy metabolism in cardiomyocytes using a model of human peripheral blood leukocytes.
Materials and methods. Sixty Wistar rats were divided into groups: 1) intact rats; 2) rats with experimental myocardial ischemia; 3) rats with myocardial ischemia, which were injected with cardiocytoprotector – trimetazidine, 4) meldonium, 5) cytoflavin and 6) ethoxydol. Animals were taken out of the experiment 10 days after the administration of drugs by decapitation. The activities of pyruvate dehydrogenase and citrate synthase were determined in mitochondria of myocardial homogenates and in mitochondria of leukocytes by spectrophotometric methods.
Results. The decrease in pyruvate dehydrogenase and citrate synthase activity in cardiomyocytes and in leukocytes were revealed in case of myocardial ischemia modeling. The introduction of cardiocytoprotectors led to the activation of these enzymes both in heart cells and in blood leukocytes. Direct positive correlations were obtained between the activity of pyruvate dehydrogenase in the mitochondria of cardiomyocytes and in the mitochondria of leukocytes (r = 0.811; p < 0.0001); between citrate synthase activity in the mitochondria of cardiomyocytes and in the mitochondria of leukocytes (r = 0.909; p < 0.0001).
Conclusion. Changes in energy metabolism in blood leukocytes under the influence of cytoprotectors reflect similar changes occurring in heart cells.
About the Authors
A. L. Khokhlov
Yaroslavl State Medical University
Russian Federation
Russian Federation
Alexander L. Khokhlov – Dr. Sc. (Med.), Member of the RAS, Professor, Head of the Department of Pharmacology and Clinical Pharmacology, Rector
Revolyutsionnaya str. 5, Yaroslavl 150000
O. V. Romashchenko
Yaroslavl State Medical University; Belgorod State National Research University
Russian Federation
Russian Federation
Olesya V. Romashchenko – Cand. Sc. (Med.), Docent, Associate Professor at the Department of Pharmacology and Clinical Pharmacology
Pobedy str. 85, Belgorod 308015
V. V. Rumbesht
Belgorod State National Research University
Russian Federation
Russian Federation
Vadim V. Rumbesht – Cand. Sc. (Techn.), Docent, Associate Professor at the Department of Mathematical and Software Information Systems
Pobedy str. 85, Belgorod 308015
T. I. Yakunchenko
Belgorod State National Research University
Russian Federation
Russian Federation
Tatyana I. Yakunchenko – Dr. Sc. (Med.), Professor, Head of the Department of Propaedeutics of Internal Medicine and Clinical Information Technologies of the Medical Institute
Pobedy str. 85, Belgorod 308015
N. I. Zhernakova
Belgorod State National Research University
Russian Federation
Russian Federation
Nina I. Zhernakova – Dr. Sc. (Med.), Professor, Head of the Department of Family Medicine of the Medical Institute
Pobedy str. 85, Belgorod 308015
L. R. Zakirova
Belgorod State National Research University
Russian Federation
Russian Federation
Lyudmila R. Zakirova – Candidate of Biological Sciences, Associate Professor, Associate Professor at the Department of Biochemistry of the Medical Institute
Pobedy str. 85, Belgorod 308015
V. G. Kukes
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Vladimir G. Kukes – Dr. Sc. (Med.), Professor, Academician of the Russian Academy of Sciences, Honorary Professor of the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases
Trubetskaya str. 8, build. 2, Moscow 119048
References
1. 2020 Clinical practice guidelines for stable coronary artery disease. Russian Journal of Cardiology. 2020; 25(11): 4076. (In Russ.). doi: 10.15829/1560-4071-2020-4076
2. 2020 Clinical practice guidelines for chronic heart failure. Russian Journal of Cardiology. 2020; 25(11): 4083. (In Russ.). doi: 10.15829/1560-4071-2020-4083
3. Umehara T, Oka H, Nakahara A, Matsuno H, Murakami H. Differential leukocyte count is associated with clinical phenotype in Parkinson’s disease. J Neurol Sci. 2020; 409: 116638. doi: 10.1016/j.jns.2019.116638
4. Vinodh Rajkumar R. Exercise Performance and Immune Competence [EPIC: Background of natural immunity, immune diversity and immuno-iatrogenesis. Int J Physiother Res. 2022; 10(3): 4250-4268. doi: 10.16965/ijpr.2022.124
5. Schirrmacher V. Mitochondria at work: New insights into regulation and dysregulation of cellular energy supply and metabolism. Biomedicines. 2020; 8(11): 526. doi: 10.3390/biomedicines8110526
6. Zuurbier CJ, Bertrand L, Beauloye CR, Andreadou I, Ruiz‐Meana M, Jespersen NR, et al. Cardiac metabolism as a driver and therapeutic target of myocardial infarction. J Cell Mol Med. 2020; 24(11): 5937-5954. doi: 10.1111/jcmm.15180
7. Dard L, Blanchard W, Huber C, Lacombe D, Rossignol R. Mitochondrial functions and rare diseases. Mol Aspects Med. 2020; 71: 100842. doi: 10.1016/j.mam.2019.100842
8. Sukhorukov VS. Individual peculiarities of tissue energy metabolism and their role in the development of childhood diseases. Russian Bulletin of Perinatology and Pediatrics. 2011; 56(2): 4-11. (In Russ.)
9. Huang Z, Xie N, Illes P, Di Virgilio F, Ulrich H, Semyanov A, et al. From purines to purinergic signalling: Molecular functions and human diseases. Signal Transduct Target Ther. 2021; 6(1): 162. doi: 10.1038/s41392-021-00553-z
10. Romanov BK. Lysosome enzyme activity as a new diagnostic and prognostic criterium for the evaluation of cardiomyocyte damage rate. I.P. Pavlov Russian Medical Biological Herald. 2004; 1-2: 155-163. (In Russ.).
11. Dambrova M, Zuurbier CJ, Borutaite V, Liepinsh E, Makrecka-Kuka M. Energy substrate metabolism and mitochondrial oxidative stress in cardiac ischemia/reperfusion injury. Free Radic Biol Med. 2021; 165: 24-37. doi: 10.1016/j.freeradbiomed. 2021.01.036
12. Vasyuk YuA, Kulikov KG, Kudryakov ON, Krikunova OV, Sadulaeva IA. Secondary mitochondrial dysfunction in acute coronary syndrome. Rational Pharmacotherapy in Cardiology. 2007; 3(1): 41-47. (In Russ.). doi: 10.20996/1819-6446-2007-3-1-41-47
13. Vuononvirta J, Marelli-Berg FM, Poobalasingam T. Metabolic regulation of T lymphocyte motility and migration. Mol Aspects Med. 2021; 77: 100888. doi: 10.1016/j.mam.2020.100888
14. Hortová‐Kohoutková M, Lázničková P, Frič J. How immune‐cell fate and function are determined by metabolic pathway choice: The bioenergetics underlying the immune response. Bioessays. 2021; 43(2): 2000067. doi: 10.1002/bies.202000067
15. Koterov AN, Ushenkova LN, Zubenkova ES, Vaynson AA, Biryukov AP. Age relationships between major laboratory animals (mice, rats, hamsters and dogs) and humans: Relevance to age-related radiosensitivity and analysis of published data. Medical Radiology and Radiation Safety. 2018; 63(1): 5-27. (In Russ.). doi: 10.12737/article_5a82e4a3908213.56647014
16. Rogozhina AA, Averkova AO, Zubova YeA, Minushkina LO, Brazhnik VA, Ivanova ON, et al. Incidence of familial hypercholesterolemia in patients with early manifestations of coronary artery disease: Data from a Russian multicenter study and metaanalysis. Russian Journal of Cardiology. 2023; 28(10): 5587. (In Russ.). doi: 10.15829/1560-4071-2023-5587
17. Putilina FYe. Method for determining citrate synthase activity. In: Methods of biochemical research (lipid and energy metabolism). Ed. by M.I. Prokhorova. Leningrad: Leningrad University Publ., 1982: 179-181. (In Russ.).
18. Yeshchenko ND. Method for determining pyruvate dehydrogenase activity. In: Methods of biochemical research (lipid and energy metabolism). Ed. by M.I. Prokhorova. Leningrad: Leningrad University Publ., 1982: 192-195. (In Russ.).
19. Prochownik EV, Wang H. The metabolic fates of pyruvate in normal and neoplastic cells. Cells. 2021; 10(4): 762. doi: 10.3390/cells10040762
20. Maurer J, Hoene M, Weigert C. Signals from the circle: Tricarboxylic acid cycle intermediates as myometabokines. Metabolites. 2021; 11(8): 474. doi: 10.3390/metabo11080474
21. Roosterman D, Cottrell GS. Rethinking the citric acid cycle: Connecting pyruvate carboxylase and citrate synthase to the flow of energy and material. Int J Mol Sci. 2021; 22(2): 604. doi: 10.3390/ijms22020604
22. Guo Y, Pu WT. Cardiomyocyte maturation: New phase in development. Circ Res. 2020; 126(8): 1086-1106. doi: 10.1161/CIRCRESAHA.119.315862
23. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000; 86(5): 580-588. doi: 10.1161/01.res.86.5.580
24. Bobescu E, Marceanu LG, Dima L, Balan A, Strempel CG, Covaciu A. Trimetazidine therapy in coronary artery disease: The impact on oxidative stress, inflammation, endothelial dysfunction, and long-term prognosis. Am J Ther. 2021; 28(5): e540-e547. doi: 10.1097/MJT.0000000000001430
25. Romashchenko OV. Personalized trimetazidine prescription as a cytoprotective agent in patients with coronary artery disease. Russian Journal of Cardiology. 2021; 26(6): 106-114. (In Russ.). doi: 10.15829/1560-4071-2021-4532
26. Larina VN. Multisystem effect of cytoprotection. Consilium Medicum. 2021; 23(1): 93-98. (In Russ.). doi: 10.26442/20751753.2021.1.200732
27. Berlato DG, de Bairros AV. Meldonium: Pharmacological, toxicological, and analytical aspects. Toxicology Research and Application. 2020; 4. doi: 10.1177/2397847320915143
28. Nedogoda SV. Meldonium as a supernosological drug. Consilium Medicum. 2020; 22(5): 57-61. (In Russ.). doi: 10.26442/20751753.2020.5.200208
29. Shivakumar A, Yogendra Kumar MS. Critical review on the analytical mechanistic steps in the evaluation of antioxidant activity. Crit Rev Anal Chem. 2018; 48(3): 214-236. doi: 10.1080/10408347.2017.1400423
30. Zhigacheva VI, Krikunova IN, Binyukov IV, Mil E, Rusina I, Goloshchapov A. Etoxidol as a broad spectrum adaptogen. Curr Mol Pharmacol. 2023; 16(1): 109-115. doi: 10.2174/1874467215666220308115514
31. Romaschenko O, Pokrovsky M, Nadezhdin S, Rumbesht V, Zhernakova N, Alferov P, et al. Personalized approaches to the use of the antioxidant ethoxidol in patients with coronary heart disease. Journal of Nanostructures. 2022; 12(2): 343-352. doi: 10.22052/JNS.2022.02.011
32. Novikov VE, Levchenkova OS, Ivantsova EN, Vorobieva VV. Mitochondrial dysfunctions and antihypoxants. Reviewers on Clinical Pharmacology and Drug Therapy. 2019; 17(4): 30-41. (In Russ.). doi: 10.7816/RCF17431-42
33. Romashchenko O.V. The influence of cytoflavin on the viability of blood leukocytes in patients with ischemic heart disease. Experimental and Clinical Pharmacology. 2021; 84(3): 17-21. (In Russ.). doi: 10.30906/0869-2092-2021-84-3-17-21
Review
For citations:
Khokhlov A.L., Romashchenko O.V., Rumbesht V.V., Yakunchenko T.I., Zhernakova N.I., Zakirova L.R., Kukes V.G. Leukocyte as an adequate model for studying changes in energy metabolism in heart cells under the influence of cardiocytoprotectors in myocardial ischemia. Acta Biomedica Scientifica. 2024;9(5):114-121. https://doi.org/10.29413/ABS.2024-9.5.12
Views:
217
.png)
Email this article 
